The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of ...

2023年8月17日，UBS调整了对GE HealthCare Technologies Inc. (NASDAQ:GEHC)的立场，将该股评级从中性下调至卖出。该公司还将目标价从之前的84美元下调至74美元。 UBS分析师表示，当前股价已充分反映了预期收益，但未考虑潜在风险，尤其是来自中国市场的风险，这促使他们做出了这一举动。 GE HealthCare的股价今年大幅上涨，涨幅约为20%，接近历 ...

伊利诺伊州阿灵顿高地 - GE HealthCare (NASDAQ: GEHC) 获得美国食品和药物管理局（FDA）批准，可使用Flyrcado™（氟吡啶F 18）注射液，这是一种新型正电子发射断层扫描（PET）心肌灌注成像（MPI）剂。Flyrcado旨在检测冠状动脉疾病（CAD），与当前标准的单光子发射计算机断层扫描（SPECT）MPI相比，具有更高的诊断效能。 Flyrcado的批准基于其 ...

Selvan Senthivel is the new chief technology officer for the 6-year-old Seattle startup. Senthivel was most recently CTO for ...

GE HealthCare (NASDAQ:GEHC) was cut to sell by UBS on Thursday, with the bank asserting that rewards were already priced into ...

Fintel reports that on September 26, 2024, UBS downgraded their outlook for GE HealthCare Technologies ( BVC:GEHC) from ...

GE HealthCare (Nasdaq: GEHC) today announced its latest innovations in radiation oncology that will be showcased at the ...

GE HealthCare has received approval for Flyrcado, its enhanced diagnosis tool for coronary heart disease, from the Food and Drug Administration. The company said on Friday that Flyrcado, or ...

In a report released yesterday, Ryan Zimmerman from BTIG upgraded GE Healthcare Technologies Inc (GEHC – Research Report) to a Buy, with ...

GE HealthCare (Nasdaq: GEHC) announced today that it launched its enhanced Venue Sprint point-of-care ultrasound system ...

GE HealthCare Technologies Inc. is a leading provider in the healthcare sector, specializing in the development, manufacture, and marketing of a wide range of products and digital solutions.